Axa
FSTX

Axa’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Axa’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-94,545
Closed -$1.3M – 1354
2019
Q3 		$1.3M Sell
94,545
-166
-0.2% -$2.74K 0.01% 941
2019
Q2 		$1.4M Buy
94,711
+2,056
+2% +$55.1K 0.01% 912
2019
Q1 		$3.89M Hold
92,655
– – 0.02% 709
2018
Q4 		$3.85M Hold
92,655
– – 0.02% 674
2018
Q3 		$4.47M Hold
92,655
– – 0.02% 704
2018
Q2 		$4.39M Buy
92,655
+26,685
+40% +$1.48M 0.02% 683
2018
Q1 		$4.06M Sell
65,970
-676
-1% -$35.7K 0.02% 705
2017
Q4 		$3.58M Buy
66,646
+4,714
+8% +$280K 0.01% 734
2017
Q3 		$4.17M Buy
61,932
+8,501
+16% +$487K 0.02% 663
2017
Q2 		$2.89M Buy
+53,431
New +$2.47M 0.01% 720

Other funds holding FSTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Axa's FSTX Position: Q4 2019 in Review

Axa sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2019, closing a stake of 94,545 shares — an estimated $1.3M sold.

Axa first reported a position in FSTX in Q2 2017 and held it in 10 quarters. The position peaked at $4.47M in Q3 2018. 31 funds tracked by Wall St. Rank hold FSTX as of Q4 2019.

  • Axa reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Axa sold 94,545 F-star Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $1.3M.
  • Axa first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2017 and held it in 10 quarters.
  • Axa's F-star Therapeutics, Inc. Common Stock position peaked at $4.47M in Q3 2018.
  • 31 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Axa's 13F filing for Q4 2019, filed 18 Feb 2020.